Menu

Home / Guides / Ozempic and GLP-1 vision loss

From the FDA, the EMA and the studies.

Ozempic vision loss: what the FDA, the EMA and the studies say about NAION

By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated

NAION, a rare eye condition that causes sudden, painless vision loss in one eye, may be more likely on Ozempic and other GLP-1 medicines. On Nov. 9, 2026, the FDA required a NAION warning on every GLP-1 label, tirzepatide included; in June 2025, the EMA’s safety committee concluded NAION is a very rare side effect of semaglutide, which may affect up to 1 in 10,000 people taking it. Sudden change in your vision? Get eye care right away.

  • FDA, Nov. 9, 2026: NAION warning required for every GLP-1 label
  • EMA, June 2025: very rare with semaglutide, up to 1 in 10,000
  • Vision change? Get eye care now; ask your prescriber before stopping

NAION, in the data regulators reviewed

In 126 GLP-1 trials
6.4 per 100,000 person-years, vs 3.8
Probable cases there
10 on GLP-1s, vs 5 on placebo
EMA, for semaglutide
Very rare: up to 1 in 10,000 people
Adults over 50, in general
2.3–10.2 per 100,000 a year
US label warning
Required for every GLP-1, Nov. 9, 2026

Sources: FDA Drug Safety Communication, Nov. 9, 2026, and the EMA’s statement, June 6, 2025; read Nov. 18, 2026.

Sudden change in your vision? Get eye care right away. Questions about your medicine? Call or text (949) 818-8000, 24/7.

Check my eligibility

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · LegitScript certified

About 3 minutes of health questions. No insurance needed.

Compounded medicines aren’t FDA-approved. A NexLife provider prescribes one only if it offers a significant difference for you compared with an FDA-approved medicine.

At a glance

Ozempic vision loss at a glance

The short answers, from the FDA, the EMA, the US labels and eye specialists. Each one is explained below, with its date.

Ozempic vision loss: the short answers, from the FDA’s Nov. 9, 2026, safety communication, the EMA’s June 6, 2025, statement, the US prescribing information read Nov. 18, 2026, and the American Academy of Ophthalmology
QuestionAnswer
What is NAION?A rare optic nerve condition that can cause sudden, painless vision loss in one eye, which can be permanent.
Can Ozempic cause it?Possibly. The EMA concluded it is a very rare side effect of semaglutide (June 2025); the FDA calls the risk potential (Nov. 2026).
How rare is it?In 126 trials the FDA pooled: 6.4 cases per 100,000 person-years on a GLP-1, versus 3.8 on comparators. The EMA: up to 1 in 10,000 people on semaglutide.
Which medicines?The FDA’s warning covers every GLP-1 medicine, including Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound and Foundayo. The EMA’s finding covers semaglutide.
What are the warning signs?Sudden, painless vision loss in one eye, which you may notice on waking; blurred or missing areas; blind spots or tunnel vision; distorted colors; hazy spots in the center.
What should you do?Get eye care right away, the same day, and tell your prescriber. Don’t stop or change your medicine on your own.
Should everyone stop?Neither the FDA nor the EMA says so. If NAION is confirmed, the EMA says to stop semaglutide; the FDA says to decide with your provider.
And diabetic eye disease?A separate label warning: with diabetes, a rapid improvement in blood sugar has been linked to a temporary worsening of retinopathy.
Compounded semaglutide?Ozempic, Rybelsus and Wegovy are the FDA-approved brands. Compounded versions are made by a pharmacy, aren’t FDA-approved and aren’t reviewed by the FDA for safety, effectiveness or quality. The NAION findings concern the approved products; whichever you take, watch for the warning signs above.

The studies and labels concern FDA-approved brand-name medicines. Compounded semaglutide and tirzepatide are made by a pharmacy, aren’t FDA-approved and weren’t studied for NAION.

  1. Tell us about you About 3 minutes of health questions
  2. A licensed provider decides You’re prescribed only if it’s right for you
  3. Your partner pharmacy ships Usually within 1 to 2 business days, free

Key takeaways

  • A rare risk, now required on every label: on Nov. 9, 2026, the FDA required a warning about NAION, a rare cause of sudden vision loss in one eye, for every GLP-1 medicine, Ozempic and tirzepatide included.
  • How rare: in 126 trials the FDA pooled, 6.4 cases per 100,000 person-years on a GLP-1, versus 3.8 on comparators. The EMA calls it very rare with semaglutide: up to 1 in 10,000 people.
  • Still debated: the FDA calls the risk potential. Studies range from no increase (2025) to hazard ratios of 4.28 and 7.64 in one center’s patients (2024).
  • Sudden vision change? Get eye care right away, the same day, and say you take a GLP-1. The FDA says to contact your provider right away.
  • Don’t stop on your own: talk to your prescriber first. If NAION is confirmed, the EMA says to stop semaglutide; the FDA says to decide with your provider.
  • Diabetic eye disease is a separate warning: with diabetes, a rapid improvement in blood sugar has been linked to a temporary worsening of retinopathy, the labels say, so report any vision change.
  • Compounded semaglutide and tirzepatide are made by a pharmacy, aren’t FDA-approved and aren’t reviewed by the FDA for safety, effectiveness or quality; the NAION findings concern the FDA-approved brands. Watch for the warning signs. At NexLife, real people answer 24/7 at (949) 818-8000.

The condition

What is NAION?

NAION, short for non-arteritic anterior ischemic optic neuropathy, is a rare condition in which blood flow to the front of the optic nerve drops and vision in one eye is suddenly lost or dimmed. The FDA says its underlying cause isn’t fully understood.

“…acute, painless, decreased vision in one eye, including permanent vision loss.”

U.S. Food and Drug Administration, describing NAION in its Drug Safety Communication, Nov. 9, 2026

How do you notice it?

Most often as sudden, painless vision loss in one eye, which you may notice when you wake up. The FDA’s list of signs also includes blurred or missing parts of your vision, blind spots or tunnel vision, distorted colors, and blurry or hazy spots in the center. What to do if you notice one.

Can lost vision come back?

Usually not. The American Academy of Ophthalmology (AAO) says vision lost to ischemic optic neuropathy is usually permanent and that no treatment improves it, though people with severe cases usually keep some side vision. Prompt care still matters: finding and treating the problem early can help prevent further loss, it says.

Who may be at higher risk?

The FDA lists possible risk factors: smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. People who have had NAION are at higher risk of it coming back, and if it affects one eye, the other eye is at higher risk. If you’ve ever had it, tell your prescriber before you start a GLP-1.

How is it different from diabetic eye disease?

NAION affects the optic nerve. Diabetic retinopathy affects the retina, and the labels carry a separate warning about it for people with diabetes (see below).

From the FDA’s Drug Safety Communication of Nov. 9, 2026, and the AAO’s patient page, What Is Ischemic Optic Neuropathy? (reviewed Apr. 27, 2023), both read Nov. 18, 2026.

Warning signs

What are the warning signs, and how fast should you get help?

Right away. The FDA says to contact your health care professional right away if you notice any of these signs, and tells prescribers to refer anyone with suspected NAION to an eye specialist (ophthalmologist) promptly.

Get eye care right away, the same day. Call your eye doctor or your provider; if you can’t reach anyone, go to an emergency room. Say that you take a GLP-1 medicine, and which one.

  • Sudden vision loss in one eye

    Painless, and you may first notice it when you wake up.

  • Blurred or missing parts of what you see

    Part of the view in one eye is blurred or gone.

  • Blind spots or tunnel vision

    A spot you can’t see through, or losing the edges of your view.

  • Colors that look distorted

    Colors don’t look the way they usually do.

  • A hazy or blurry center

    Blurry or hazy spots in the middle of your vision, so detail is harder to see.

  • Any other sudden change in one eye

    The FDA asks prescribers to have patients report any visual change in one eye right away.

Already had your eyes checked?

Tell your prescriber what the eye doctor found before your next dose. NexLife members can call or text (949) 818-8000, 24/7: a real person answers, gets your question to your provider, follows up with the pharmacy if it’s about your medicine, and gets back to you with the next step.

Signs from the FDA’s Drug Safety Communication of Nov. 9, 2026, read Nov. 18, 2026. This list doesn’t replace an eye exam.

Step by step

Should you stop taking your GLP-1 medicine?

Not on your own. Neither the FDA nor the EMA tells people without symptoms to stop; their advice is about what to do if NAION happens. Talk to your prescriber before you stop or change anything.

  1. No symptoms? Keep to your prescription and learn the warning signs. If the news worries you, ask your prescriber; don’t stop on your own.
  2. Sudden change in your vision? Get eye care the same day. An eye doctor checks your optic nerve with a dilated eye exam and may order other tests.
  3. Tell your prescriber what happened and what the eye doctor found, before your next dose.
  4. If NAION is confirmed, decide together. The EMA says semaglutide should be stopped. The FDA says to talk with your provider about continuing or stopping, and tells prescribers to consider stopping unless the benefits clearly outweigh the risk.
  5. Weigh what stopping means, too. The AAO and the North American Neuro-Ophthalmology Society don’t back a blanket rule to stop, because stopping can carry significant health risks; they favor a shared decision with your doctors.

From the FDA (Nov. 9, 2026), the EMA (June 6, 2025) and the AAO and NANOS (July 7, 2025), read Nov. 18, 2026. Your prescriber’s instructions come first.

Regulators

What did the FDA and the EMA conclude, and when?

Europe moved first. In June 2025 the EMA’s safety committee concluded NAION is a very rare side effect of semaglutide; in November 2026 the FDA required a NAION warning on the label of every GLP-1 medicine sold in the US.

  1. A study in JAMA Ophthalmology, from one academic center in Boston, reports more NAION in patients prescribed semaglutide. The FDA later noted several limitations.

  2. The EMA’s safety committee (PRAC) concludes NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy, meaning it may affect up to 1 in 10,000 people taking semaglutide, and recommends adding it to their product information.

  3. The AAO and the North American Neuro-Ophthalmology Society say they don’t support a blanket rule to stop semaglutide, and favor shared decisions.

  4. The FDA requires the makers of every GLP-1 medicine to add the potential NAION risk to the Warnings and Precautions section of their labels.

  5. The US labels we read don’t list NAION in their warnings yet: Ozempic (revised May 2026), Rybelsus and Ozempic tablets (January 2026), Wegovy (June 2026), Mounjaro and Zepbound (August 2026). The FDA didn’t say when updated labels will appear.

“If NAION is confirmed, treatment with semaglutide should be stopped.”

European Medicines Agency, PRAC statement on semaglutide and NAION, June 6, 2025

The FDA’s advice differs on one point. It tells patients who have had NAION to talk with their health care professional about whether to keep taking their GLP-1 medicine or stop it, and tells prescribers to consider stopping it “unless the benefits of treatment clearly outweigh the risk.”

  • 6.4 NAION cases per 100,000 person-years on GLP-1s, in trials
  • 3.8 on placebo or other diabetes medicines
  • Up to 1 in 10,000 people on semaglutide, the EMA says
  • 2.3–10.2 per 100,000 adults over 50 a year, in general

From the FDA’s Drug Safety Communication of Nov. 9, 2026, and the EMA’s statement of June 6, 2025 (updated June 13, 2025), both read Nov. 18, 2026, with each label as revised on the date shown.

How rare

How rare is NAION on Ozempic and other GLP-1s?

Rare. In 126 trials the FDA pooled, there were 15 probable cases among 134,253 people: 10 on GLP-1 medicines and 5 on placebo. That’s 6.4 cases per 100,000 person-years on a GLP-1, versus 3.8 on comparators.

NAION and GLP-1 medicines: what each regulator review and study found, who it covered and its limits. Numbers exactly as published; read Nov. 18, 2026
Source and dateWho and howWhat it foundLimits and context
FDA, pooled trials
Nov. 9, 2026
126 randomized trials; 134,253 people; 288,879 person-years15 probable cases: 10 on GLP-1s, 5 on placebo. 6.4 vs 3.8 cases per 100,000 person-yearsEach trial had few or no cases, so the FDA pooled them
FDA Sentinel records
Nov. 9, 2026
US health records of adults with type 2 diabetes starting a medicine in 2019–202426 to 32 cases per 100,000 person-years in every group. GLP-1s vs DPP-4 inhibitors: hazard ratio 1.43 (95% CI 1.02–2.01); vs SGLT-2 inhibitors: 1.19 (0.91–1.54), not significantHealth records, not a trial; type 2 diabetes only
EMA safety committee
June 6, 2025
Several large epidemiological studies, plus trials and post-marketing reports, on semaglutideAbout twice the risk in adults with type 2 diabetes: about 1 extra case per 10,000 person-years. Trials point to a slightly higher riskConcluded it is a very rare side effect; the statement doesn’t name the studies
Hathaway et al., JAMA Ophthalmology
July 3, 2024
16,827 patients seen by neuro-ophthalmology at one academic center in Boston, 2017–2023; retrospective, matched groupsType 2 diabetes (194 on semaglutide, 516 on other diabetes medicines): 17 vs 6 cases, hazard ratio 4.28 (1.62–11.29). Overweight or obesity (361 on semaglutide, 618 on other weight-loss medicines): 20 vs 3 cases, hazard ratio 7.64 (2.21–26.36)One center and few cases; observational, and the authors say more study is needed to assess cause. The FDA noted several limitations
OHDSI network study, JAMA Ophthalmology
April 2025
14 databases; 37.1 million adults with type 2 diabetes, 810,390 of them new semaglutide users; 2017–202314.5 cases per 100,000 person-years among semaglutide users. No significant difference against three other diabetes drugs with the broader case definition; hazard ratio 2.27 (1.16–4.46) against empagliflozin with the stricter one; a rate ratio of 1.32 (1.14–1.54) in a self-controlled analysisDiagnosis codes; the authors call the increase modest, and smaller than reported before
TriNetX study, American Journal of Ophthalmology
June 2025
US health records, matched 1:1: about 120,000 on semaglutide with type 2 diabetes, about 58,000 with overweight or obesityNo increase: 5-year risk ratio 0.7 (0.523–0.937) for semaglutide in type 2 diabetes, and no increase with overweight or obesityHealth records; everyone had an eye or neurology visit; no case counts in the abstract
Adults over 50, in general
FDA, Nov. 9, 2026
Published studies of the general population2.3 to 10.2 cases per 100,000 people a yearNAION also happens without these medicines

What a person-year means. One person followed for one year. So 6.4 per 100,000 person-years is about 6 cases a year for every 100,000 people taking a GLP-1.

Why the studies disagree. The first study drew on patients already seen by one center’s neuro-ophthalmology service and had few cases, so its confidence intervals are wide (1.62 to 11.29, and 2.21 to 26.36). Later, larger studies found smaller increases or none: about twice the risk in the studies the EMA reviewed, a modest rise in the 2025 network study, and no increase in the 2025 TriNetX study.

What it means for you. NAION is uncommon with or without these medicines. Regulators now treat it as a possible side effect; how much GLP-1s add to the risk is still debated. If you have a risk factor such as sleep apnea, or you’ve had NAION before, ask your prescriber whether it changes anything for you.

Every row links to its source; the 2024 study’s figures were checked against its abstract in JAMA Ophthalmology on Nov. 18, 2026. None of these studies reported results for compounded versions, which aren’t FDA-approved.

Tirzepatide

Does the NAION warning apply to tirzepatide?

Yes, in the US. The FDA’s Nov. 9, 2026, requirement covers every GLP-1 medicine, and its list includes Mounjaro and Zepbound (tirzepatide). It says NAION has been reported with every GLP-1 medicine now sold, but it gave no numbers for tirzepatide alone.

What did the EMA say about tirzepatide?

Nothing, in its NAION statement. The EMA’s June 2025 conclusion names semaglutide medicines only: Ozempic, Rybelsus and Wegovy.

What do the tirzepatide labels say now?

The Mounjaro and Zepbound labels (both revised August 2026) don’t list NAION in their warnings yet. Both say temporary worsening of diabetic retinopathy has been reported with rapid improvement in blood sugar, and that people with a history of it should be monitored. Both tell patients to contact their provider if their vision changes (Zepbound’s says this to people with type 2 diabetes).

Did the studies look at tirzepatide?

Not separately. The studies in the table above looked at semaglutide, or at GLP-1 medicines as a group, and none reported tirzepatide results on its own. If you take tirzepatide, the warning signs and what to do are the same. More: tirzepatide side effects and Mounjaro vs. Zepbound.

From the FDA (Nov. 9, 2026), the EMA (June 6, 2025) and the Mounjaro and Zepbound prescribing information (revised August 2026), read Nov. 18, 2026.

The labels

What do the labels say about diabetic eye disease?

Each semaglutide and tirzepatide label we read has a separate warning for people with diabetes: a rapid improvement in blood sugar has been linked to a temporary worsening of diabetic retinopathy, and people with a history of it should be monitored.

Diabetic retinopathy in the US prescribing information, by label and revision date, read Nov. 18, 2026
LabelWhat it reports
Ozempic
Revised May 2026
In a 2-year trial of people with type 2 diabetes and high heart risk, retinopathy complications in 3.0% on Ozempic vs 1.8% on placebo: 8.2% vs 5.2% in people who already had retinopathy, 0.7% vs 0.4% in those who didn’t.
Rybelsus and Ozempic tablets
Revised January 2026
Retinopathy-related side effects in 4.2% on semaglutide tablets vs 3.8% on comparators in blood-sugar trials, plus the 2-year injection trial above.
Wegovy
Revised June 2026
In a weight trial of people with type 2 diabetes, retinopathy reported in 4% on Wegovy vs 2.7% on placebo, plus the 2-year trial above.
Mounjaro and Zepbound
Revised August 2026
No percentages: temporary worsening has been reported with rapid improvement in blood sugar; anyone with a history of retinopathy should be monitored.

What the labels ask you to do. Contact your provider if your vision changes during treatment, the Ozempic, Rybelsus, Wegovy, Mounjaro and Zepbound labels say; Wegovy’s and Zepbound’s say this to people with type 2 diabetes. People with a history of retinopathy should be monitored for changes.

How this differs from NAION. Retinopathy is a diabetes complication in the retina, and its temporary worsening has been linked to blood sugar improving fast. NAION affects the optic nerve, and the FDA’s new warning applies to every GLP-1 label, with or without diabetes. Comparing the semaglutide brands? Ozempic vs. Wegovy and semaglutide vs. Ozempic.

From the prescribing information for Ozempic (May 2026), Rybelsus and Ozempic tablets (January 2026), Wegovy (June 2026), Mounjaro and Zepbound (August 2026), sections 5 and 17, read Nov. 18, 2026.

Compounded

Does the warning apply to compounded semaglutide or tirzepatide?

The FDA hasn’t said. Wegovy, Ozempic and Rybelsus (semaglutide) and Zepbound and Mounjaro (tirzepatide) are the FDA-approved brand-name medicines, and what their labels and the studies say about NAION concerns those products. Compounded versions are made by a pharmacy, aren’t FDA-approved, aren’t reviewed by the FDA for safety, effectiveness or quality, and weren’t studied for NAION.

“…does not review compounded drugs for safety, effectiveness or quality before they are marketed.”

U.S. Food and Drug Administration, FDA’s concerns with unapproved GLP-1 drugs used for weight loss, content current as of Oct. 1, 2026
  1. What the FDA’s notice covers

    Its Nov. 9, 2026, requirement applies to the makers of FDA-approved GLP-1 medicines, and the notice doesn’t mention compounded versions.

  2. What the FDA’s compounded-drug page shows

    As of May 31, 2026, the FDA had 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. That page doesn’t mention eye problems either way.

  3. What to do if you take one

    Watch for the warning signs above, and get eye care right away if one appears. You or your provider can report a problem to the FDA’s MedWatch program. More: compounded vs. brand-name semaglutide.

Where NexLife’s vials come from. NexLife’s orders are filled by two state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL) and Boudreaux’s New Drug Store (Lake Charles, LA). More about NexLife’s pharmacy partners.

Dose and vial math

What does each dose look like in a syringe?

If you use a vial, check your dose in units every time. From a vial, it depends on the strength; here it is at an example strength of 25 mg per mL.

Each tirzepatide dose in mL and units on a U-100 syringe, at an example strength of 25 mg per mL. Example only: your vial’s label decides.
Weekly doseVolume at 25 mg/mL (example)Units on a U-100 syringe
2.5 mg0.1 mL10 units
5 mg0.2 mL20 units
7.5 mg0.3 mL30 units
10 mg0.4 mL40 units
12.5 mg0.5 mL50 units
15 mg0.6 mL60 units

The math: mL = dose ÷ strength (mg per mL); units = mL × 100. So 7.5 mg ÷ 25 mg/mL = 0.3 mL, or 30 units. 25 mg/mL is an example only: it’s the strength of Zepbound’s 15 mg multi-dose vial on its August 2026 FDA label. Your vial’s label decides the strength, and your prescription sets your dose.

Check before you draw. The FDA has reported dosing errors with compounded semaglutide, and says mix-ups between milliliters, milligrams and units may have contributed. If a number doesn’t match your prescription, ask your provider before you inject. Drew too much? See what to do if you took too much tirzepatide. Every dose and strength: our tirzepatide dosage chart.

Loved by our members

Real stories from NexLife members about their care and service.

A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.

★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗

  • ★★★★★Read on Trustpilot ↗

    “So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”

    April

  • ★★★★★Read on Trustpilot ↗

    “Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”

    Ethan B.

  • ★★★★★Read on Trustpilot ↗

    “That’s a real site with good prices and plans!”

    Estefany L.

  • ★★★★★Read on Trustpilot ↗

    “Affordable, quick and easy. They could not have made it a smoother less stressful experience.”

    Andisheh K.

  • ★★★★★Read on Trustpilot ↗

    “Great communication. Easy to work with. They work to set you up for success.”

    Anthony C.

  • ★★★★★Read on Trustpilot ↗

    “Fast delivery and easy to get a hold of when needing to talk with someone!”

    Browneyes

  • ★★★★★Read on Trustpilot ↗

    “Great service and excellent communication!”

    Gabrielle D.

  • ★★★★★Read on Trustpilot ↗

    “Easy and pricing not bad! Customer service was helpful in answering my questions.”

    Lyndy T.

  • ★★★★★Read on Trustpilot ↗

    “Good experience, great team”

    Mai S.

  • ★★★★★Read on Trustpilot ↗

    “Great communciation and was fast and reliable”

    Kiki

  • ★★★★★Read on Trustpilot ↗

    “Very happy so far”

    Tammy E.

  • ★★★★★Read on Trustpilot ↗

    “Fast service great communication!! Willing to work with you!”

    Bon

Names are shortened for privacy. Reviews are members’ opinions, not medical advice.

What would you pay with NexLife?

Tap where you are now. We’ll show your NexLife price next to it, or tell you we’ll match it.

Pick one above to see your price.

Check my eligibility
Not today?

Prices from each provider’s own site, checked November 1, 2026. Brand-name and compounded medications are different products: compounded medications aren’t FDA-approved, and a provider prescribes one only when it offers a significant difference for you. Price Match Guarantee† terms apply.

What does NexLife cost?
One flat price at every dose.

No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†

Illustration of a compounded tirzepatide vialGIP + GLP-1

12-month plan $115/mo

Tirzepatide

Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

Illustration of a compounded semaglutide vialGLP-1

12-month plan $95/mo

Semaglutide

Weekly GLP-1. Care, coaching and shipping included. On a 12-month plan, $1,140 paid upfront; $109/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms

The NexLife Price Match Guarantee†

Paying less elsewhere?
Keep your price. Upgrade your care.

Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.

  1. 1Send a receipt from the last 60 days
  2. 2A NexLife provider reviews your prescription
  3. 3Pay your matched price, at every dose
Switch and keep my price

Locked while your plan is activeSame price at every doseNo membership fee

†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.

Ozempic vision loss: your questions

Fair questions about NexLife

Will my price go up with my dose?
No. You pay the same at every dose.
What if I’m not prescribed?
You aren’t charged for medication.
Can I cancel?
Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
Do I need insurance?
No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.

Can Ozempic cause vision loss?

Possibly, but it’s rare. In June 2025 the EMA concluded that NAION, a cause of sudden vision loss in one eye, is a very rare side effect of semaglutide, the ingredient in Ozempic, meaning it may affect up to 1 in 10,000 people taking semaglutide. On Nov. 9, 2026, the FDA required a NAION warning on every GLP-1 label, calling the risk potential. If your vision changes suddenly, get eye care right away.

What is NAION?

Non-arteritic anterior ischemic optic neuropathy: a rare condition in which blood flow to the front of the optic nerve drops, causing sudden, painless vision loss in one eye. The FDA says its underlying cause isn’t fully understood, and the American Academy of Ophthalmology says vision lost to ischemic optic neuropathy is usually permanent.

How common is NAION on semaglutide or tirzepatide?

Rare. In 126 trials the FDA pooled, NAION came to 6.4 cases per 100,000 person-years on GLP-1 medicines, versus 3.8 on comparators, with 15 probable cases in all (Nov. 9, 2026). The EMA puts it at up to 1 in 10,000 people on semaglutide. In adults over 50 in general, it occurs in 2.3 to 10.2 per 100,000 people a year.

Does the NAION warning apply to Mounjaro and Zepbound?

Yes, in the US. The FDA’s Nov. 9, 2026, requirement covers every GLP-1 medicine, including tirzepatide (Mounjaro, Zepbound), though it gave no tirzepatide-only numbers. The EMA’s June 2025 conclusion covers semaglutide only. The Mounjaro and Zepbound labels (revised August 2026) don’t list NAION in their warnings yet.

What are the warning signs of NAION?

Sudden, painless vision loss in one eye, which you may notice on waking; blurred or missing parts of your vision; blind spots or tunnel vision; distorted colors; and blurry or hazy spots in the center of your vision, the FDA says (Nov. 9, 2026). If you notice any of them, get eye care right away.

What should I do if my vision suddenly changes on a GLP-1?

Get eye care right away, the same day: call your eye doctor or provider, or go to an emergency room if you can’t reach anyone, and say which GLP-1 you take. Then tell your prescriber what the eye doctor found. Don’t stop or change your dose on your own; decide with them.

Should I stop taking Ozempic because of NAION?

Not on your own. Neither the FDA nor the EMA tells people without symptoms to stop. If NAION is confirmed, the EMA says semaglutide should be stopped (June 2025), the FDA says to talk with your provider about continuing or stopping (Nov. 2026), and the AAO and NANOS favor a shared decision, since stopping can carry its own health risks (July 2025).

Is vision loss from NAION permanent?

Usually. The American Academy of Ophthalmology says vision lost to ischemic optic neuropathy is usually permanent and that no treatment improves it, though people with severe cases usually keep some side vision. Prompt care still matters: finding and treating the problem quickly can help prevent further loss, it says.

Who is at higher risk of NAION?

The FDA lists possible risk factors: smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. If you’ve had NAION, you’re at higher risk of it coming back, and the other eye is at higher risk too. Tell your prescriber before starting a GLP-1 if you’ve ever had it.

Can Ozempic make diabetic eye disease worse?

It can in some people with type 2 diabetes. In a 2-year trial in the Ozempic label (revised May 2026), retinopathy complications occurred in 3.0% on Ozempic versus 1.8% on placebo, and in 8.2% versus 5.2% of people who already had retinopathy. The label notes that rapid improvement in blood sugar has been linked to temporary worsening, and says to report vision changes.

What does the NAION warning mean for compounded semaglutide?

The FDA hasn’t said. Ozempic, Rybelsus and Wegovy are the FDA-approved brand-name semaglutide medicines, and what their labels and the studies say about NAION concerns those products. Compounded semaglutide is made by a pharmacy, isn’t FDA-approved, isn’t reviewed by the FDA for safety, effectiveness or quality, and wasn’t studied for NAION. The FDA’s Nov. 9, 2026, notice doesn’t mention it, so watch for the warning signs.

Do the FDA and the EMA agree?

Mostly. The EMA (June 2025) called NAION a very rare side effect of semaglutide and said to stop semaglutide if NAION is confirmed. The FDA (Nov. 2026) required a warning for every GLP-1 and said patients who have had NAION should talk with their provider about continuing or stopping.

Important safety information

Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2).

Read the full safety information

In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other GLP-1 medicines.

Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.

This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.

About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.

“Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”

U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers

Who wrote and medically reviewed this page?

Adam Kennah, MDMedical Director, NexLife · Board-certified in emergency medicine (American Board of Emergency Medicine) · NPI 1144260043

Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.

NexLife Medical TeamWrites and updates NexLife’s guides

Checked every number against the FDA’s Nov. 9, 2026, safety communication, the EMA’s June 6, 2025, statement and the US labels, read Nov. 18, 2026.

  • How we checked. Regulator statements come from the FDA and the EMA, and label facts from Novo Nordisk’s and Eli Lilly’s prescribing information, all read Nov. 18, 2026. Study results come from their published abstracts, read Nov. 18, 2026. We don’t diagnose or give a dosing plan: your prescriber decides.
  • Every fact, sourced. Each price and rule links to the page it comes from.
  • How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
  • Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
  • How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves

Paying less elsewhere? We match it.†

Questions don’t wait for office hours. Neither do we.

Compounded tirzepatide is $115 a month on a 12-month plan, or $129 month to month, at every dose, with real people on call 24/7.

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified

Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.

  1. 1
    Tell us about you

    Start online with your health history.

  2. 2
    A licensed provider decides

    Online, following your state’s rules. You’re prescribed only if treatment is right for you.

  3. 3
    We ship it, then stay with you

    Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.

Sources

  1. U.S. Food and Drug Administration. FDA requires safety labeling changes for GLP-1 receptor agonists due to potential increased risk of rare but serious eye condition (NAION). Drug Safety Communication, Nov. 9, 2026. Read Nov. 18, 2026.
  2. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 6, 2025, updated June 13, 2025. Read Nov. 18, 2026.
  3. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. Revised May 2026. Read Nov. 18, 2026.
  4. Novo Nordisk. Rybelsus and Ozempic (semaglutide) tablets prescribing information. Revised January 2026. Read Nov. 18, 2026.
  5. Novo Nordisk. Wegovy (semaglutide) prescribing information. Revised June 2026. Read Nov. 18, 2026.
  6. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. Revised August 2026. Read Nov. 18, 2026.
  7. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. Revised August 2026. Read Nov. 18, 2026.
  8. National Library of Medicine. DailyMed: Ozempic (semaglutide) injection label. Updated June 1, 2026; checked Nov. 18, 2026 for a newer version.
  9. JAMA Ophthalmology. Semaglutide and nonarteritic anterior ischemic optic neuropathy (OHDSI network study). 2025;143(4):304-314. PubMed record. Read Nov. 18, 2026.
  10. American Journal of Ophthalmology. The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy. 2025;274:24-31. PubMed record. Read Nov. 18, 2026.
  11. JAMA Ophthalmology. Hathaway JT, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. 2024;142(8):732-739. Published online July 3, 2024 (doi:10.1001/jamaophthalmol.2024.2296). Read Nov. 18, 2026.
  12. American Academy of Ophthalmology. What is ischemic optic neuropathy? Reviewed Apr. 27, 2023. Read Nov. 18, 2026.
  13. American Academy of Ophthalmology and North American Neuro-Ophthalmology Society. Should you stop taking GLP-1 drugs like Ozempic if you experience vision loss? News release, July 7, 2025. Read Nov. 18, 2026.
  14. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of Oct. 1, 2026. Read Nov. 18, 2026.
  15. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Read November 15, 2026.
  16. U.S. Food and Drug Administration. MedWatch: report a problem.
  17. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. Read November 15, 2026.
  18. Eli Lilly and Company, via Drugs@FDA. ZEPBOUND (tirzepatide) injection, for subcutaneous use: prescribing information, revised February 2026. Read November 15, 2026.
  19. LegitScript. LegitScript certification record for NexLife.us.
  20. NexLife. Compounded tirzepatide plans.
  21. NexLife. Compounded semaglutide plans.